The new oral anticoagulants may prove to be one of the most significant innovations in
clinical practice in the past 60 years. Apixaban and rivaroxaban are specific inhibitors of …

Currently available anticoagulants include heparin, low-molecular-weight heparin,
fondaparinux and warfarin. Despite advances, currently available agents have limitations …

Vitamin K antagonists were the only class of oral anticoagulants available to clinicians for
decades. However, with the US Food and Drug Administration approval of new oral …

Venous thromboembolic disease, including deep vein thrombosis and pulmonary embolism,
is a cause of significant mortality and morbidity. For several decades, anticoagulant options …

Purpose Data comparing traditional and novel anticoagulants are reviewed, and the
potential use of new oral agents for the prevention and treatment of venous …

After years of only oral vitamin K antagonists, there are new many new antithrombotic agents
in development and on entering the marketplace. This review will analyze clinical trial …

Betrixaban is a direct factor Xa inhibitor with a renal excretion of only approximately 5–7%.
On June 23rd 2017, it became the first direct oral anticoagulant to receive Food and Drug …

Traditional therapeutic oral anticoagulation strategies often require invasive dosing or
monitoring. Vitamin K antagonists (VKAs) have a large number of interactions, delayed …

Warfarin was the only oral anticoagulant available for the treatment of venous
thromboembolism for about half a century until the recent approval of novel oral agents …

From the 1940s through 2010, warfarin (Coumadin, Bristol-Myers Squibb) was the only oral
anticoagulant on the market in the US for the treatment and prevention of thromboembolic …